DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers
- 1 October 1993
- journal article
- Published by Springer Nature in Human Genetics
- Vol. 92 (4) , 367-372
- https://doi.org/10.1007/bf01247337
Abstract
Deficient debrisoquine/sparteine type oxidation is inherited as an autosomal recessive trait. Of all Caucasians, 5–10% are poor metabolisers, due to the absence of cytochrome P4502D6. Extensive metabolisers (EMs) exhibit highly variable metabolic activity. We investigated the relationship between CYP2D6 activity and genotypes of the CYP2D locus in a large set of French Caucasian families. Genotypes concern both common mutations affecting the enzyme activity and linkedBamHI polymorphisms of the locus. We found, like other authors, that in EMs part of the heterogeneity is explained by a subgroup of individuals heterozygous for a mutant allele. However, a second level of heterogeneity was detected among individuals not carrying mutations, and this was related to a polymorphicBamHI-defined DNA haplotype. Different combinations of haplotypes are associated with differences in CYP2D6 metabolic activity. This finding might help to clarify the conflicting data on the relation between CYP2D6 activity and susceptibility to lung cancer.Keywords
This publication has 32 references indexed in Scilit:
- Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.British Journal of Clinical Pharmacology, 1993
- Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotypePharmacogenetics, 1991
- Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypesPharmacogenetics, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Detection of debrisoquine hydroxylation phenotypesThe Lancet, 1990
- Molecular genotyping to predict debrisoquine hydroxylation phenotypeThe Lancet, 1990
- Identification of the primary gene defect at the cytochrome P450 CYP2D locusNature, 1990
- Recent Developments in Hepatic Drug OxidationClinical Pharmacokinetics, 1990
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- Metabolic oxidation phenotypes as markers for susceptibility to lung cancerNature, 1984